|
1) Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27: 1492-501
|
|
|
|
2) Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14: 309-17
|
|
|
|
|
|
3) Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkinʼs lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001; 86: 485-93
|
|
|
|
|
|
4) Kanekal S, Crain B, Elliott G, et al. SDX-105 (TreandaTM) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts. Blood. 2004; 104: 229b (abstr 4580)
|
|
|
|
|
|
5) Schöffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol. 2000; 11: 729-34
|
|
|
|
|
|
6) Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydro-chloride administered day 1＋2 every 3 weeks in patients with solid tumours. Br J Cancer. 2007; 96: 1692-8
|
|
|
|
|
|
7) Ogura M, Uchida T, Taniwaki M, et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010; 101: 2054-8
|
|
|
|
|
8) Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009; 27: 4378-84
|
|
|
|
|
|
9) Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia. A multicenter phase II trial of the German chronic lymphocytic leukemia Study Group. J Clin Oncol. 2011; 29: 3559-66
|
|
|
|
|
|
10) Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkinʼs lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008; 26: 204-10
|
|
|
|
|
|
11) Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010; 116: 106-14
|
|
|
|
|
|
12) Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010; 101: 2059-64
|
|
|
|
|
|
13) Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkinʼs lymphoma. J Clin Oncol. 2005; 23: 3383-9
|
|
|
|
|
|
14) Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkinʼs lymphoma. J Clin Oncol. 2008; 26: 4473-9
|
|
|
|
|
|
15) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts). 2009; 114: 405
|
|
|
|
|
|
16) Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas: final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts). 2010; 116: 856
|
|
|
|
|
|
17) Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkinʼs lymphoma. Ann Oncol. 2002; 13: 1285-9
|
|
|
|
|
|
18) Ogura M, Ando K, Taniwaki M, et al. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin lymphoma. Cancer Sci. 2011; 102: 1687-92
|
|
|
|
|
|
19) Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011; 22: 1839-44
|
|
|
|
|
|
20) Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132: 205-12
|
|
|
|
|